Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index; 58 of the 197 sources its claims cite were checked for support.
Abstract
Although the study of cognitive disengagement syndrome (CDS; previously called sluggish cognitive tempo) first emerged in the 1980s, very little is known about treating CDS or its impact on evidence-based interventions for attention-deficit/hyperactivity disorder (ADHD) with which it frequently co-occurs. The objective of this leading article was to investigate the existing evidence on medication treatment and CDS, including studies that have examined CDS response to medication and CDS as a moderator of ADHD treatment response. A total of seven studies were identified. At present, the limited existing literature suggests that psychostimulants such as methylphenidate and lisdexamfetamine, as well as atomoxetine, may improve CDS symptoms, although replication and research on related medications is needed. However, there are indications that CDS symptoms may predict a reduced response to methylphenidate in children with ADHD. Although untested, research on the neurobiological, neuropsychological, and behavioral correlates of CDS point to a possible benefit of other ADHD medications (e.g., guanfacine), medications that treat narcolepsy (e.g., modafinil), and medications traditionally used to treat depression and anxiety (e.g., viloxazine, bupropion, fluvoxamine), some of which have also recently been used in ADHD management. The article concludes with recommendations for future research on pharmacologic treatment and CDS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 Valid · 0 Not valid · 51 Not checked · 12 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“given the high comorbidity with ADHD (i.e., 25–40% of youth with ADHD have elevated CDS symptoms) [6-9]”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Introduction
What the sources say
- Not checked yetcites [6] Barkley RA. Distinguishing sluggish cognitive tempo from ADHD in children and adolescents: executive functioning, impairment, and comorbidity. J Clin Child Adoles Psychol. 2013;42(2):161–73. https://doi.org/10.1080/15374416.2012.734259. source
- Supportedcites [7] Servera M, Sáez B, Burns GL, et al. Clinical differentiation of sluggish cognitive tempo and attention-deficit/hyperactivity disorder in children. J Abnormal Psychol. 2018;127(8):818. https://doi.org/10.1037/abn0000375. source
The Abstract reports that 27–35% of children in the clinically elevated ADHD group also met criteria for elevated SCT, within the claimed 25–40% range. The study used symptom-rating cutoffs in children aged 8–13, rather than confirmed ADHD diagnoses. (LLM, conf=0.92)
- Supportedcites [8] Burns GL, Becker SP. Sluggish cognitive tempo and ADHD symptoms in a nationally representative sample of US children: differentiation using categorical and dimensional approaches. J Clin Child Adolesc Psychol. 2021;50(2):267–80. https://doi.org/10.1080/15374416.2019.1678165. source
The Results section reports that 49 of 142 children meeting the study’s criteria for ADHD also had elevated SCT symptoms—about 35%, within the claimed 25–40% range. The paper uses the term SCT for the symptoms the claim calls CDS. (LLM, conf=0.93)
- Not checked yetcites [9] Carlson CL, Mann M. Sluggish cognitive tempo predicts a different pattern of impairment in the attention deficit hyperactivity disorder, predominantly inattentive type. J Clin Child Adolesc Psychol. 2002;31(1):123–9. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, there are indications that CDS symptoms may predict a reduced response to methylphenidate in children with ADHD.”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Abstract
What the sources say
- Not checked yetcites [51] Fırat S, Gul H, Aysev A. An open-label trial of methylphenidate treating sluggish cognitive tempo, inattention, and hyperactivity/impulsivity symptoms among 6-to 12-year-old ADHD children: what are the predictors of treatment response at home and school? J Atten Disord. 2021;25(9):1321–30. https://doi.org/10.1177/1087054720902846. source
- Supportedcites [57] Froehlich TE, Becker SP, Nick TG, et al. Sluggish cognitive tempo as a possible predictor of methylphenidate response in children with ADHD: a randomized controlled trial. J Clin Psychiatry. 2018;79(2):19052. source
The Discussion reports that elevated Sluggish/Sleepy symptoms, one aspect of SCT (also called CDS), predicted a less robust methylphenidate response in children with ADHD. The claim is appropriately hedged; the finding does not extend to the Daydreamy factor. (LLM, conf=0.92)
- Not checked yetcites [58] Ludwig HT, Matte B, Katz B, et al. Do sluggish cognitive tempo symptoms predict response to methylphenidate in patients with attention-deficit/hyperactivity disorder-inattentive type? J Child Adolesc Psychopharmacol. 2009;19(4):461–5. https://doi.org/10.1089/cap.2008.0115. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overall, this research points toward a link between CDS and impairments in sustained goal-driven attention and re-orientation [22-26].”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Neurobiological Correlates of CDS
What the sources say
- Partly supportedcites [22] Camprodon-Rosanas E, Pujol J, Martínez-Vilavella G, et al. Brain structure and function in school-aged children with sluggish cognitive tempo symptoms. J Am Acad Child Adolesc Psychiatry. 2019;58(2):256–66. https://doi.org/10.1016/j.jaac.2018.09.441. sourceExperimental — accuracy not yet measured
The discussion (pp. 16–17) links sluggish cognitive tempo (SCT) symptoms to alterations in a dorsal frontal network involved in sustained attention and goal-oriented behavior. It does not establish an impairment in attentional re-orientation; the reference to a reorienting system on p. 26 is a cited work’s title, not a finding about these children. (LLM, conf=0.84)
- Not checked yetcites [23] Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron. 2008;58(3):306–24. https://doi.org/10.1016/j.neuron.2008.04.017. source
- Partly supportedcites [24] Fassbender C, Krafft CE, Schweitzer JB. Differentiating SCT and inattentive symptoms in ADHD using fMRI measures of cognitive control. Neuroimage Clin. 2015;8:390–7. https://doi.org/10.1016/j.nicl.2015.05.007. sourceExperimental — accuracy not yet measured
The Conclusion (page not available in our copy) says that reduced left superior parietal lobule activity in adolescents with ADHD who had more SCT symptoms may reflect impaired reorientation or shifting of attention. The Discussion cautions that this did not translate into poorer performance. These passages support the proposed link to reorientation, but do not establish an impairment in sustained goal-driven attention. (LLM, conf=0.84)
- Not checked yetcites [25] Kardaş B, Baytunca B, Bolat GÜ, et al. An investigation of cranial functional magnetic resonance imaging results in children and adolescents with attention deficit and hyperactivity disorder and sluggish cognitive tempo (SCT). Int J Child Health Hum Dev. 2021;14(1):21–33.
- Not checked yetcites [26] Jarrett MA, Gable PA, Rondon AT, et al. An EEG study of children with and without ADHD symptoms: between-group differences and associations with sluggish cognitive tempo symptoms. J Atten Disord. 2020;24(7):1002–10. https://doi.org/10.1177/1087054717723. doi:10.1177/1087054717723
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Still, research has shown that CDS is unique from ADHD, as evidenced by many studies documenting different structures and phenomenology [2, 10, 11], neuropsychological profiles [10, 12-14], and correlates”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Introduction
What the sources say
- Partly supportedcites [2] Becker SP, Leopold DR, Burns GL, et al. The internal, external, and diagnostic validity of sluggish cognitive tempo: a meta-analysis and critical review. J Am Acad Child Adoles Psychiatry. 2016;55(3):163–78. https://doi.org/10.1016/j.jaac.2015.12.006. sourceExperimental — accuracy not yet measured
The Results (Factor Analyses; page unavailable) find SCT to be a symptom dimension separable from ADHD, and the Results (SCT in Relation to Other Psychopathologies; page unavailable) describe different patterns of correlates. But the Results (SCT in Relation to Neuropsychological and Executive Functioning; page unavailable) call the neuropsychological findings mixed and say more work is needed, so the claim overstates how firmly different neuropsychological profiles have been established. (LLM, conf=0.86)
- Supportedcites [10] Willcutt EG, Chhabildas N, Kinnear M, et al. The internal and external validity of sluggish cognitive tempo and its relation with DSM-IV ADHD. J Abnormal Child Psychol. 2014;42(1):21–35. https://doi.org/10.1007/s10802-013-9800-6. source
The Abstract (page not provided) reports a separate SCT symptom factor, and the Discussion on internal validity describes its low-energy, sleepy and sluggish features. The Results on external validity report distinct neuropsychological associations and functional-impairment correlates after controlling for ADHD symptoms. The paper also cautions that SCT and ADHD symptoms are correlated; distinct does not mean wholly separate. (LLM, conf=0.88)
- Not checked yetcites [11] McBurnett K, Villodas M, Burns GL, et al. Structure and validity of sluggish cognitive tempo using an expanded item pool in children with attention-deficit/hyperactivity disorder. J Abnormal Child Psychol. 2014;42(1):37–48. https://doi.org/10.1007/s10802-013-9801-5. source
- Not checked yetcites [12] Barkley RA, Willcutt E, Jacobson LA. What is the cognitive deficit in sluggish cognitive tempo (SCT)? A review of neuropsychological research. ADHD Rep. 2022;30(2):1–10. https://doi.org/10.1521/adhd.2022.30.2.1. source
- Supportedcites [13] Kofler MJ, Irwin LN, Sarver DE, et al. What cognitive processes are “sluggish” in sluggish cognitive tempo? J Consult Clin Psychol. 2019;87(11):1030. https://doi.org/10.1037/ccp0000446. source
This source is cited alongside others for the neuropsychological-profile portion of the sentence, not specifically for structure or phenomenology. Its Discussion reports associations of sluggish cognitive tempo with slower working-memory manipulation and faster inhibition, and says these findings remained robust after controlling for ADHD-inattention symptoms (no page number available in our copy). (LLM, conf=0.85)
- Supportedcites [14] Creque CA, Willcutt EG. Sluggish cognitive tempo and neuropsychological functioning. Res Child Adolesc Psychopathol. 2021;49(8):1001–13. https://doi.org/10.1007/s10802-021-00810-3. source
The Internal and External Validity section describes SCT symptoms and reports that they form a factor separate from ADHD symptoms. The Results and Discussion identify neuropsychological associations that remain after ADHD symptoms are controlled, supporting a distinct profile without implying that the conditions never overlap. (LLM, conf=0.90)
- Supportedcites [1] Becker SP, Willcutt EG, Leopold DR, et al. Report of a Work Group on Sluggish Cognitive Tempo: key research directions and a consensus change in terminology to cognitive disengagement syndrome. J Am Acad Child Adoles Psychiatry. 2022. https://doi.org/10.1016/j.jaac.2022.07.821. source
In Results and Discussion (SCT and Comorbidity), the paper says SCT/CDS and ADHD inattention are empirically distinct and describes different associations with hyperactivity. The SCT and Cognition section reports that several executive-function deficits common in ADHD are not consistently or strongly associated with SCT; the terminology section also describes a distinct symptom dimension and unique associations with functional outcomes. The paper cautions that neuropsychological findings have not established a central cognitive deficit. (LLM, conf=0.87)
- Not checked yetcites [6] Barkley RA. Distinguishing sluggish cognitive tempo from ADHD in children and adolescents: executive functioning, impairment, and comorbidity. J Clin Child Adoles Psychol. 2013;42(2):161–73. https://doi.org/10.1080/15374416.2012.734259. source
- Not checked yetcites [15] Becker SP, Luebbe AM, Fite PJ, et al. Sluggish cognitive tempo in psychiatrically hospitalized children: factor structure and relations to internalizing symptoms, social problems, and observed behavioral dysregulation. J Abnormal Child Psychol. 2014;42(1):49–62. https://doi.org/10.1007/s10802-013-9719-y. source
- Not checked yetcites [16] Smith ZR, Eadeh H-M, Breaux RP, et al. Sleepy, sluggish, worried, or down? The distinction between self-reported sluggish cognitive tempo, daytime sleepiness, and internalizing symptoms in youth with attention-deficit/hyperactivity disorder. Psychol Assess. 2019;31(3):365. https://doi.org/10.1037/pas0000671. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Research examining the neurobiological correlates of CDS is quite limited, though most of the current evidence points to irregularities in the dorsal attention network (DAN) and/or default mode network (DMN) [22-26].”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Neurobiological Correlates of CDS
What the sources say
- Supportedcites [22] Camprodon-Rosanas E, Pujol J, Martínez-Vilavella G, et al. Brain structure and function in school-aged children with sluggish cognitive tempo symptoms. J Am Acad Child Adolesc Psychiatry. 2019;58(2):256–66. https://doi.org/10.1016/j.jaac.2018.09.441. source
The Functional MRI results (p. 14) associate sluggish cognitive tempo symptoms with reduced segregation between the studied networks, including the default mode network. The discussion (p. 17) identifies the implicated dorsal frontal region as part of the dorsal attentional network and describes anomalies in these networks. This paper supports the network finding attributed to it within a sentence citing several studies. (LLM, conf=0.90)
- Not checked yetcites [23] Corbetta M, Patel G, Shulman GL. The reorienting system of the human brain: from environment to theory of mind. Neuron. 2008;58(3):306–24. https://doi.org/10.1016/j.neuron.2008.04.017. source
- Partly supportedcites [24] Fassbender C, Krafft CE, Schweitzer JB. Differentiating SCT and inattentive symptoms in ADHD using fMRI measures of cognitive control. Neuroimage Clin. 2015;8:390–7. https://doi.org/10.1016/j.nicl.2015.05.007. sourceExperimental — accuracy not yet measured
The Results (fMRI data; page unavailable) link more SCT symptoms to lower activity in the left superior parietal lobule among adolescents with ADHD, supporting an attention-related neural irregularity. The paper does not identify this finding as a dorsal attention network abnormality or establish a default mode network abnormality in CDS; its Discussion mentions default-network connectivity only in relation to ADHD. It also does not assess whether most current CDS evidence points to those networks. (LLM, conf=0.84)
- Not checked yetcites [25] Kardaş B, Baytunca B, Bolat GÜ, et al. An investigation of cranial functional magnetic resonance imaging results in children and adolescents with attention deficit and hyperactivity disorder and sluggish cognitive tempo (SCT). Int J Child Health Hum Dev. 2021;14(1):21–33.
- Not checked yetcites [26] Jarrett MA, Gable PA, Rondon AT, et al. An EEG study of children with and without ADHD symptoms: between-group differences and associations with sluggish cognitive tempo symptoms. J Atten Disord. 2020;24(7):1002–10. https://doi.org/10.1177/1087054717723. doi:10.1177/1087054717723
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
51 more claims · 17 with their cited sources checked
Create a free account to see all 92 claims and to verify the 139 references still open.
- It may state two separate claims as one. 26
- The quote only partly states this claim. 1
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“given that only a limited number of studies have explored the effectiveness of interventions in reducing symptoms related to CDS and its associated impairments [4,77].”
From Emotional Dysregulation and Cognitive Disengagement Syndrome: Exploring Their Relationship Through the Lens of Twin Studies (2025) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > Pharmacotherapy Studies for the Treatment of CDS
“A recent open-label trial of 185 children (ages 8–12 years) with ADHD examined parent and teacher ratings”
§ Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research > CDS as a Moderator of Treatment Response for ADHD
“a smaller improvement in total ADHD symptoms in 185 children (aged 6–12 years) with ADHD”
Citations
Cites
The reorienting system of the human brain: from environment to theory of mind
Corbetta, M., Patel, G., & Shulman, G. L. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.017 · Cited by 3,889 · cited 12×
“295 CDS (SCT) Medication Treatments and Recommendations for Future Research the re-orienting response, allowing for goal-driven attention to break as necessary to re-orient and respond to relevant stimuli in the environment [23].”
BackgroundMethodResultInfluentialThe Science of Mind Wandering: Empirically Navigating the Stream of Consciousness
Smallwood, J., & Schooler, J. W. (2015) · Annual Review of Psychology · doi:10.1146/annurev-psych-010814-015331 · Cited by 1,685 · cited 1×
“This is also consistent with emerging work showing that CDS is related to more self-reported mind-wandering [45, 46], which is defined by internally focused thoughts [47].”
ResultModafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 1×
“Modafinil, which is approved by the US Food and Drug Administration for the treatment of narcolepsy and its associated daytime sleepiness [59], is a logical candidate to address the hypoactive/sleepy aspects of CDS.”
BackgroundReaction time variability in ADHD: A meta-analytic review of 319 studies
Kofler, M. J., Rapport, M. D., Sarver, D. E., Raiker, J. S., Orban, S. A., Friedman, L. M., & Kolomeyer, E. G. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.06.001 · Cited by 648 · cited 1×
“While increased reaction time variability and deficits in working memory have been clearly documented in ADHD [48, 49], research to date has been variable with respect to whether these deficits also apply to CDS [12].”
BackgroundScahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588 · cited 1×
“The alpha-agonist guanfacine may also provide benefit, given previous evidence that individuals with CDS may have a propensity toward signal detection errors [2, 10, 14, 39, 44] and that guanfacine may ameliorate errors of omission in individuals with ADHD [61, 62].”
BackgroundKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464 · cited 1×
“Beneficial effects of atomoxetine on CDS symptoms (which include hypoactivity/sleepiness) are notable given the side-effect profile of atomoxetine in participants with ADHD, with 15–17% experiencing somnolence with atomoxetine (vs 2–4% with placebo) in controlled trials [55, 56].”
BackgroundBarkley, R. A. (2013) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2012.734259 · Cited by 398 · cited 3×
“3 Neuropsychological Correlates of CDS Prior studies have examined neuropsychological and cognitive correlates of CDS [1, 6, 12].”
BackgroundBecker, S. P., Leopold, D. R., Burns, G. L., Jarrett, M. A., Langberg, J. M., Marshall, S. A., McBurnett, K., Waschbusch, D. A., & Willcutt, E. G. (2016) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.12.006 · Cited by 368 · cited 6×
“Some researchers have also called for research examining whether selective serotonin-reuptake inhibitors, such as fluvoxamine, fluoxetine, or sertraline, may be beneficial in the treatment of CDS given the higher prevalence of anxiety and depression in individuals experiencing CDS [1, 2, 6, 10, 11, 15, 16], as well as…”
BackgroundInfluentialSelf-citationCarlson, C. L., & Mann, M. (2002) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3101_14 · Cited by 342
Dimensions and types of attention deficit disorder
LAHEY, B. B., PELHAM, W. E., SCHAUGHENCY, E. A., ATKINS, M. S., MURPHY, H. A., HYND, G., RUSSO, M., HARTDAGEN, S., & LORYS-VERNON, A. (1988) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-198805000-00011 · Cited by 313 · cited 1×
“The ventral attention network is the network that works in tandem with the DAN with respect to attention-deficit/hyperactivity disorder (ADHD) inattentive symptom dimension [4, 5].”
Background
Research works printed but not linked: 3
- Kardaş B, Baytunca B, Bolat GÜ, et al. An investigation of cranial functional magnetic resonance imaging results in children and adolescents with attention deficit and hyperactivity disorder and sluggish cognitive tempo (SCT). Int J Child Health Hum Dev. 2021;14(1):21–33.
- Barkley RA. Barkley sluggish cognitive tempo scale-children and adolescents (BSCTS-CA). New York: Guilford; 2018.
- Achenbach TM, Edelbrock C. Child behavior checklist. Burlington (Vt). 1991;7:371–92.
Cited by
Wiggs, K. K., Thornton, K., Dunn, N. C., Mitchell, J. T., Fredrick, J. W., Smith, Z. R., & Becker, S. P. (2024) · Journal of Attention Disorders · doi:10.1177/10870547241290182 · Cited by 18
Self-citationBahmani, D. S., Parhoon, H., Esmaeili, M., Parhoon, K., Bahmani, L. S., Khazaie, H., Becker, S. P., Burns, G., & Brand, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144607 · Cited by 15
“Third, several studies among non-adult samples with CDS have shown that children and adolescents scoring high on CDS might respond differently to evidence-based treatments for ADHD [47–49].”
BackgroundSelf-citationBahmani, D. S., Eisenhut, L., Mikoteit, T., Helfenstein, N., Brühl, A. B., Dürsteler, K. M., Bizimana, J.-M., Becker, S. P., & Brand, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145165 · Cited by 12
“First, interventions to improve CDS are scarce, mixed, and often at the level of pilot studies and open trials, ranging from the administration of ADHD-recommended stimulants to mindfulness awareness practices [1,2,6,8,65,66].”
Self-citationFerreira, M., Carneiro, P., Costa, V. M., Carvalho, F. D., Meisel, A., & Capela, J. P. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0016 · Cited by 11
Cui, H., Shu, C., Peng, Y., Wei, Z., Ni, X. Y., Zheng, L., Shang, J., Liu, F., & Liu, J. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116766 · Cited by 8
Metadata
- Authors
- Wiggs, K. K., Froehlich, T. E., & Becker, S. P.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Becker, Stephen P.
- Venue
- CNS Drugs
- Published
- 2023-04
- Volume
- 37
- Issue
- 4
- Pages
- 293-304
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC12376379
- OpenAlex
- W4365815190
- Semantic Scholar
- 70534cb916630d99bfa1e3e63037516c88699f56
- Cited by
- 16
- References
- 73
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 6 · 2023: 1
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH122415)
- Institute of Education Sciences (R305A200028)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- cognitive disengagement syndrome, sluggish cognitive tempo, attention deficit hyperactivity disorder, methylphenidate, lisdexamfetamine, atomoxetine, guanfacine, modafinil, viloxazine, bupropion, fluvoxamine, treatment moderators, children
- MeSH terms
- Atomoxetine Hydrochloride, Lisdexamfetamine Dimesylate, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Cognition, Humans, Methylphenidate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. https://app.cochat.ai/papers/10.1007/s40263-023-00999-5
- The paper
- Wiggs, K. K., Froehlich, T. E., & Becker, S. P. (2023). Pharmacologic Management of Cognitive Disengagement Syndrome (CDS) and Implications for Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: Emerging Treatments and Recommendations for Future Research. CNS Drugs. https://doi.org/10.1007/s40263-023-00999-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.